History and development of incretin effect:the evidence and promise of incretin-based therapies in the clinical practice / 中华内分泌代谢杂志
Chinese Journal of Endocrinology and Metabolism
;
(12): 629-633, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-709978
ABSTRACT
The discovery and development of incretin effect has changed the landscape of diabetes treatment over past decades. Nowadays, incretin-based agents, such as glucagon-like peptide-1 ( GLP-1) receptor agonists and dipeptidyl peptidase-4 ( DPP-4) inhibitors have been wildly used in the therapy of type 2 diabetes. These agents show the beneficial effects on the multiple pathophysiological defects of type 2 diabetes, and provide a safe approach for achieving glycemic control with low risk of hypoglycemia and weight gain. Moreover, incretin-based therapies are still in development. Novel incretin-related therapies, such as fixed-dose combinations of GLP-1 receptor agonists and basal insulins, oral GLP-1 receptor agonists, and GLP-1 secretagogues, will be available in clinical practice in the near future.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Endocrinology and Metabolism
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS